The ICR collects information from
administrators of public human genetic variant databases who apply
for recognition of their database to support clinical validity for
genetic and genomic-based in vitro diagnostics. The information
collected will be used by FDA to ensure the process by which
administrators of genetic variant databases could voluntarily apply
to FDA for recognition, and how FDA would review such applications
and periodically reevaluate recognized databases. FDA believes that
if administrators of genetic variant databases follow the
recommendations, including transparency regarding evidence
evaluation, and obtain FDA recognition as described, the data and
assertions within would generally constitute valid scientific
evidence that can be used to support clinical validity.
On behalf of this Federal agency, I certify that
the collection of information encompassed by this request complies
with 5 CFR 1320.9 and the related provisions of 5 CFR
1320.8(b)(3).
The following is a summary of the topics, regarding
the proposed collection of information, that the certification
covers:
(i) Why the information is being collected;
(ii) Use of information;
(iii) Burden estimate;
(iv) Nature of response (voluntary, required for a
benefit, or mandatory);
(v) Nature and extent of confidentiality; and
(vi) Need to display currently valid OMB control
number;
If you are unable to certify compliance with any of
these provisions, identify the item by leaving the box unchecked
and explain the reason in the Supporting Statement.